Baxter/Alpha Aralast
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Baxter/Alpha Therapeutics' Aralast is approved Dec. 23 as augmentation therapy in patients who have congenital deficiency of alpha-1 proteinase inhibitor with clinically evident emphysema. The only other A1-PI on the market, Bayer's Prolastin, has been experiencing supply problem